Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.77 |
| ▸ | CTSL | P07711 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.64 |
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | MAX | P61244 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.54 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249101 | 0.91 | CTSV (0.86) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL354532 | 0.87 | CTSV (1.00) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL14069980 | 0.86 | CTSV (0.77) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL7331642 | 0.86 | CTSV (0.77) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL3030579 | 0.86 | CTSV (0.77) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL5344962 | 0.85 | CTSV (0.76) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL10532509 | 0.85 | CTSV (0.67) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL13696982 | 0.84 | CTSV (0.73) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL3020359 | 0.83 | MAPT (0.79) | CTSVCTSLMAPTKMT2AMEN1 | |
| SCHEMBL10531270 | 0.83 | CTSV (0.68) | CTSVCTSLMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390650-A | Preparation method of diamine monomer containing acridone unit | 东华大学 | 2025-02-07 | — | — | CN | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1363888-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | NAT1, TERT, CCNA1 | CTSV 3412/4885CTSL 1904/4885MAPT 3949/4885 |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | TERT, ACIN1, NAT1 | CTSV 3330/4885CTSL 2241/4885MAPT 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.